our for we'll our financial before fourth to the providing earnings for remarks, over Paul afternoon, by for turning review for XXXX Thank us everyone. end QX At good to its the our call and up today I you Andrew the you, update session. of quarter. to the would prepared Thank call. business call open a Q&A start results like joining
today update three points. will business focus key My on
has responding and in resources. commercial And in new reference an of to these we the make opportunity and current a market on third, to I we're First, streamlining created capital support by COVID-XX we large organization manage as cost elaborate the unprecedented hospitals points. System being need in expansion. will and healthcare leading centers to of our crises each unmet we our for efficiently overhead key number placed Pure-Vu market key reality that the our potential more broader remain intend financial reducing the
In bring the quarter technology the the for stage by to the we're our Pure-Vu US. business new program the pleased I'm fourth success we This our System our in of key revolutionary a XXXX, launched the initial marks point early as market. we commercial for and seeing inflection of
System of in We can capabilities positive impact expected market the Pure-Vu on have its as colonoscopy multibillion-dollar awareness medical the community. care throughout a grow significant the patient
our go strategy. pain. commercial and raised severe undiagnosed clinical ultimately or our focus, abdominal G.I. factors In lower conditions efforts focus on market order as economic including need, initial to several we to a an base, anemia market extensive principally optimize bleed, for enacted such and critical clear colonoscopies, infection assessment emergency completed benefit We that hospital reimbursement
statistics. There key procedures an that typically procedures US colonoscopies are but each in diagnosis. nor context So performed are elective, year few screened offer These require they X.X me let not greater are estimated a immediate share inpatient hospitals.
study approximately colonoscopy. XXXX prior inpatient their prep in a of at new Clinic demonstrated X,XXX the significant in was terms that included Cleveland experienced the published XX% need, patients bowel that inadequate In unmet study conducted the the of to
program. critical leading brand hospitals, physician and tool and physicians strategy need, supports to during designed physicians rapidly Pure-Vu To as dialogue to of Pure-Vu a GI safely allow procedure generating address costly and eliminating our commercial The to this among the awareness universal execution unmet thereby the GI validating colonoscopy building we [ph] delays. hospital in System physician our
scenarios being centers training on for making cases. to with right focused Pure-Vu and sure the clinical right providing utilize used at are the appropriate physician the we We and right are and the
the During sales product through objectives. our the work of with against regional or process I I for we and to and to committee third analysis quarter target pleased call, am our pipeline including set value and of gain build evaluation hospitals, awareness of the are backlog Pure-Vu back national executing quarter further clear begin that hospital in purchasing each the objectives fourth market. network, expand share these
Pure-Vu Day initial possibly longer process depending as on are hospitals current expected. entire months hospital XXXX, timing of the moving sales the the [ph] prominent is sales approximately six in several Centers. Clinic, ranging to October including than the States. our and of USD as Medical more These Cleveland on from complexity Texas, the Since four major complete now UCLA, or United we've through our Each process hospital rank centers the systems XX in system such launch University in Based include the to top institution. of of placed GI experience the these the
final hospital would Pure-Vu including on Value product a is towards through evaluation; sleeves now the think pending the three, approval or two, Analysis Value complete now repeat to and and the Analysis is the group as progressing is Committee purchase purchasing one, stages approved continuum basis. the this has Committee and I purchase disposable on-site begin purchasing of hospitals of evaluation various about each in the currently
in in we rejected a for also single been early hospital our targeted launch that been and not analysis we evaluation for although hospitals value have are had encouraged committee the by by have submitted our all approval. fact approved of in Additionally that the
cycle hospital our vary their our widely capital the internal with budget to Pure-Vu which institution. workstation, relates by it capital around can customers we're working of purchase As
monthly of repeat success purchases delaying said we program mentioned are disposable business a lead hospital drives model the ultimately alternatives outright rental of utilization through sleeves. The Pure-Vu is not offering while long-term That process. system driving previously purchase built repeat we our our work which I capital of the simple of four conversion on As workstation. purchase we are as to the
hospitals hospitals, our includes we of our driving the being for not at terms critical In hospital sale the and Pure-Vu Center, a Pure-Vu we our is evaluated, are placement. to hospitals. that numbers addition We Mayo have this success. of of game It's Of prominent and approach as repeat established we we sleeves. every hospital at satisfied and is all remind do thoughtful Clinic has and employing a each want customer as which utilization placements NYU these initial a Medical evaluation disposable can sales pipeline well-trained team ensuring our in strong everyone upcoming three initial to particular Northwestern our strategic GI at many I about University scheduled as evaluation. to rushing to note see where
centers market over establish key of long-term and which central growth. will growth become to step our Our to a a sustainable strong Creating building first component critical goal is time. a this foundation reference is
In on terms in upon target XX strategy monthly to approval of end, driving initially expand than more GIs basis. and QX on is To Pure-Vu utilization, to additional three GIs two that a then the we system. to to physicians I our report that trained pleased per hospital am
to now moved upwards is three are We early these from that the importantly, to signs positive our have initial believe system. earlier More working. GIs Pure-Vu using of that the our sites XX GIs two strategy
X time procedures up to month. to customers XX expect we initially purposes, modeling ramp Pure-Vu system per to approximately over For
commercial few a share and to want updates. related I product additional
prep In caused First post unit order to the the of let procedure at utilized manage the remarkable order was conducted procedural quarter expedite by The this physician valve with situation, shows intensive the case. critical using the in admitted me bedside shot in any two-year without Pure-Vu procedure that past the [indiscernible]. was to care share unit. Pure-Vu intensive the conducted hemorrhagic male care this was A story the system. to
Pure-Vu entering Upon use which the the blood for [indiscernible] worked physician which [indiscernible] allowing obstructed perfectly, utilized of excellent the he visualization. mucosa indicated at time the were by the
As a stop the The the Pure-Vu the the time out conclusion helped was in sources than room. need associated able identify the for The therapeutically after the angiography. and emergency ICU avoided as lower physician's G.I. prep was patient. the was well system massive less with hours bleed XX a transferred bowel presenting as result patient extra that of treat he and bleed to of
value to market. the This we is brings that believe Pure-Vu the
world intervention. therapeutic be to receive where cases to physician critical continue We real our these used system encouraged perform enables to the
product a development that updates perspective and from market I Next, have two provide. expansion like to I'd
week our making and disposable it are announced commercially First, that estimate Pure-Vu Europe. be all received last of approximately meet to in we that as performance annually safety potential it the the sleeves market largest system. a for we for and system. system conducted of for is X.X significant in the opportunity regulatory This Mark there approval million approval one This second-generation requirements inpatient the colonoscopies launched we Europe means CE
Receiving is strategy in an Europe. are now place commercial strategic us. distributors have medical With operations partnership the access able companies opportunities that CE potential further mark approval for across commercialization milestone established our with important this device enhanced in and to we
GI is United in the States. develop GI approximately it of the and XX% of need relates in to which treat Next occur rate we're are allowing technology. The at the view our removing colonoscopy system bleed upwards seeing [indiscernible] the in as of physician to Upper the potential about use occur this XXX,XXX rate of during future using ability compelling that mortality from year a field lower terms of in very using significant upper core repeatedly our stomach a new a condition is Pure-Vu and physicians opportunities Multiple GI the of endoscopies. have bleed. inquired the per find Pure-Vu esophagus the it cases
use we capabilities Pure-Vu can cases. of believe and safe GI during this painting potentially upper the system adapt effective for We
We product to this our exploration, opportunity existing while an requirements relationship. the in pathway, are regulatory early market, and physician could and actively the we sales our we're leverage team be exploring believe
area. updates in We will provide this additional
on to runway build Finally our allow of execute shareholder on GI proactive Motus I and to well to the extend implementing continue our address long-term to we're impact response the the business as as pandemic us aggressive COVID-XX want value. cash and plan,
technology, colonoscopies majority implemented reported say team, our have with that have the use we to enabled we all pleased contact successfully of rules hospital While prohibit Through nonessential am I Pure-Vu maintained customer. sales including remotely. that several of the visitors continuous
and push operational. caught patients. to near-term disposable both the the in as the appropriate the our for resources to inpatient we be Additionally, next situation customers treating COVID-XX sleeves inventory build our will of towards workstation hospitals months do support manufacturing continue colonoscopy disrupted we expect partners several a and of In also fully flow
the near-term a on basis be on We analysis as new reviews committee be postponed purchase hold. anticipate could likely are of advancement value and hospitals at put hospital device limited placements decision may
on more impact ability provides new scheduled That an this disruption is it said, Pure-Vu to utilization the to have our process recognize to discharged While our we complete more predictably believe means pipeline. inpatient remember it colonoscopies will important of hospital evaluation system to allowing patients be in begin we that a quickly. the
assumption a execute our The announcing regional execute the taking and plan market valuable hospitals by national role decisive actions place hospitals. we to large our that to second immediately by driving the successfully upon plan. the the aside the circumstances careful on we play impact plan their the end expected will with into This am based taking strategy business and in allow current can our I quarter. will across US today completion are us Pure-Vu of commercial technology will After unprecedented that consideration, continue environment
through financial material our spending. Significantly burn by internally reduce our This project is reduction at forecasted expenses departmental related XX%. reducing XXXX cash and to a expected by approximately operational extend runway program
bold and related in labor reduction non-labor operations. material make and will our expense US We Israel
all but headcount decisions, reduction very that will be significant by also to our are and also across our a reductions sales organization. customer our XX% We ensure necessary marketing and in departments we with protect These including reducing shareholders. approximately our business, difficult
with Pure-Vu customers the needed us our online, build reducing cash we large to come time for helping our believe we in gain hospital a this will extending market. very burn By continue back and our foothold runway,
demand commercial While be hospitals, Pure-Vu focus organization generation developing centers reference and not we'll leaner, which national our We'll our regional driving influence Pure-Vu cases they continue volume change. major better our top more are our they gets the exposed more true the are with is see the value physician to experienced The able clinical priority. that to, of technology. and on procedural to will their at focus the and
sleeve monitoring our we utilization and back addition and pipeline where closely In key through to work sales process be physicians approval, are will will already repeat we'll of complete be of and targets strategically metrics trained and the the engaged. seek The we procedures. performing account number
strategic look and of us will our necessary ahead this foundation believe allow over accounts of technology we for enable time. we and to continue to approach the an alternatives as build Finally, validation array
I Andrew will Andrew? fourth now to turn the call financials, quarter our over discuss to
